Trials / Completed
CompletedNCT03926169
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Risankizumab is administered as a SC injection in pre-filled syringe (PFS) |
| DRUG | Placebo for risankizumab | Placebo for risankizumab is administered as a SC injection in PFS |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2021-02-02
- Completion
- 2021-08-02
- First posted
- 2019-04-24
- Last updated
- 2022-08-11
- Results posted
- 2022-08-11
Locations
59 sites across 8 countries: United States, Australia, Canada, France, Germany, Japan, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03926169. Inclusion in this directory is not an endorsement.